drugset / Trial / NCT02183467

Effect of BI 1356 as Single Dose on the QT Interval in Healthy Female and Male Subjects

NCT02183467

Phase 1 Completed 44 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

Assessment of the effect of BI 1356 or Placebo on prolongation of the QT interval

Timeline

Start
2008-01
Primary completion
2008-06
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Linagliptin Small molecule 5 mg
Subject Linagliptin Small molecule 100 mg
Comparator Moxifloxacin Small molecule

Indications

No indication recorded.